DexCom and Telix Investors Urged to Act Before Legal Deadlines
New York, Tuesday, 11 November 2025.
The Rosen Law Firm advises DexCom and Telix Pharmaceuticals investors to seek legal counsel promptly due to approaching deadlines for securities class action lawsuits. Timely action is crucial.
Background on DexCom Class Action
On November 10, 2025, the Rosen Law Firm issued an urgent reminder to investors of DexCom, Inc. (NASDAQ: DXCM) to secure legal representation before the crucial deadline of December 29, 2025, for a securities class action lawsuit. The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems without FDA approval, resulting in decreased reliability and increased health risks for users. Furthermore, the company’s claims about the G7’s improved reliability and accuracy were allegedly overstated, leading to significant regulatory and financial repercussions [1].
Telix Pharmaceuticals’ Legal Challenges
Similarly, Telix Pharmaceuticals Ltd. (NASDAQ: TLX) investors were advised to take swift legal action by January 9, 2026, as the Rosen Law Firm has filed a class action lawsuit against the company. The lawsuit claims that Telix misrepresented the progress of its prostate cancer therapeutic candidates and overstated the quality of its supply chain, which misled investors about the company’s business operations and future prospects during the class period from February 21, 2025, to August 28, 2025 [2].
Importance for Affected Investors
For investors in both DexCom and Telix Pharmaceuticals, these lawsuits represent significant opportunities to seek redress for potential financial losses due to alleged misleading statements by these companies. It is imperative for affected shareholders to contact legal counsel promptly to ensure their claims are included in the class action proceedings. The outcomes of these lawsuits may not only impact investor compensation but also influence future regulatory compliance and corporate governance practices within these companies [1][2].
Conclusion: Act Now
With the legal deadlines fast approaching, investors in DexCom and Telix Pharmaceuticals must remain vigilant and proactive in seeking legal advice. The coming weeks are critical for those who wish to participate in these class action lawsuits, as missing the deadlines could forfeit their right to potential financial recovery. Rosen Law Firm’s call to action underscores the importance of safeguarding investor rights in the face of corporate misrepresentation [1][2].